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Cellular and molecular regulation of the immune system
is exquisitely controlled in the brain and is disrupted in
neoplasia. Despite accumulation of immune cells in the
tumor microenvironment, glioblastoma (GBM) growth
persists while the mechanisms suppressing immune func-
tion remain largely unknown. Myeloid derived suppres-
sor cells (MDSCs) are a heterogeneous class of immune
cells responsible for immunomodulation through the
suppression of cytotoxic T-cells. These populations are
elevated in the peripheral blood of GBM patients, but
their roles within the GBM microenvironment are
uncharacterized. Through immunofluorescence analysis,
we identified MDSCs within human GBM specimens,
suggesting an immunosuppressive phenotype marked by
arginase 1 (Arg1) staining. We have also observed co-
localization between MDSCs and GBM cancer stem cells
(CSCs) in both human tissues and mouse xenografts,
leading to the hypothesis that CSCs recruit MDSCs to
the tumor microenvironment, promote their survival,
and that MDSCs are responsible for the immune-evasive
properties of CSCs (Fig. 1A). Intracranial (IC) injections
of CSCs into mice have led to GBM formation, expansion
of the Arg1-producing MDSCs within the marrow of
GBM-bearing mice, and increased levels of MDSCs
within the GBM microenvironment (Fig. 1B-E). CSC
conditioned media promoted decreased apoptosis and
increased Arg1 production of murine bone marrow
derived MDSCs. Our results suggest a critical role by
which GBM is able to promote immunosuppression
through the recruitment of MDSCs and a novel paradigm
of immunomodulation by CSCs in GBM.
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Figure 1 A. MDSCs detected in GBM xenografts by labeling with Sox2, CD244.1, and Arg1. Yellow arrows indicate CSCs; white arrows indicate
MDSCs. B. H&E staining of IC xenografts. C. GBM-bearing mice have increased MDSCs by flow cytometry plots (boxed area). D. Arg1 production
is increased in GBM mouse marrow. E. MDSCs are responsible for Arg1 production.
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